Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy.

To compare perioperative and short-term postoperative complication rates between patients receiving radical cystectomy (RC) after neoadjuvant chemotherapy (NAC) and patients undergoing RC alone. Secondary objectives were to compare overall survival (OS) and cancer-specific survival (CSS).

Clinico-pathological data of all patients who received RC between 1996 and 2015 were retrospectively collected. Only patients with RC for muscle-invasive bladder cancer were included in the final analysis. Short-term (30-day) postoperative complications were assessed by registering the Clavien-Dindo classification (CDC) and dividing into sub-groups: low-grade (LGC) CDC 1-2 and high-grade (HGC) CDC 3-5. To compare populations with similar age, comorbidities and preoperative creatinine, we used a propensity score-adjusted statistical model. Pre- and perioperative predictors of short-term complications were identified using uni- and multivariable models. Survival was assessed using Kaplan-Meier analysis.

A total of 491 patients undergoing RC were included, of whom 102 (20.8%) received NAC. After propensity score covariate adjustment, there was no significant difference in postoperative complications between patients undergoing NAC plus RC and RC alone with an overall complication rate of 69% and 66%, respectively. No significant differences in the 30-day HGC rates (11.76% and 11.83%, respectively) were observed. NAC plus RC patients had worse prognostic factors at baseline; nevertheless, after correction for group differences OS and CSS did not differ from RC only group (5-year OS 61.3% vs. 50.2%, and 5-year CSS 61.8% vs. 57.9% respectively, p > 0.05 for all).

In appropriately selected patients, exposure to NAC is not associated with increased short-term complications.

World journal of urology. 2018 Dec 05 [Epub ahead of print]

Uros Milenkovic, Murat Akand, Lisa Moris, Liesbeth Demaegd, Tim Muilwijk, Youri Bekhuis, Annouschka Laenen, Ben Van Cleynenbreugel, Wouter Everaerts, Hein Van Poppel, Herlinde Dumez, Maarten Albersen, Steven Joniau

Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium., University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, KU Leuven, Louvain, Belgium., Department of Urology, University Hospitals Leuven, Herestraat 49, 3000, Louvain, Belgium. .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe